Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study
American Journal of Respiratory and Critical Care Medicine · 2026
DOI: 10.1093/ajrccm/aamaf001 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, 2026. Verfasst von Carlo Castellani und 19 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto Giannina Gaslini, Genova, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Indoles, Quinolones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vertex Pharmaceuticals.
Abstract (Originalsprache)
Rationale
Elexacaftor/tezacaftor/ivacaftor, a CF transmembrane conductance regulator (CFTR) modulator, stabilizes and restores F508del-CFTR function, which is the most common CFTR variant. In multiple clinical and real-world studies, elexacaftor/tezacaftor/ivacaftor was shown to be safe and highly effective in people with CF carrying at least one F508del-CFTR (∼80% of people with CF).
Objectives
To characterize the response of rare, non-F508del CFTR variants to elexacaftor/tezacaftor/ivacaftor in vitro, and in clinical and real-world studies.
Methods
We engineered Fischer rat thyroid (FRT) cells each of which express 1 of 620 rare exonic CFTR variants present in public databases and evaluated their in vitro response to elexacaftor/tezacaftor/ivacaftor. We evaluated efficacy and safety of elexacaftor/tezacaftor/ivacaftor in a 24-week randomized, placebo-controlled, Phase 3 trial (445-124) in participants with 1 of 18 rare variants and no F508del and in a real-world study (CFD-016) in people carrying 82 rare variants and no F508del. Measurements and Main Results In FRT cells, 518 of 620 (84%) rare variants responded to elexacaftor/tezacaftor/ivacaftor. In 445-124, mean improvements were seen in the primary endpoint of percent predicted FEV1 (9.2 percentage points [95% CI: 7.2, 11.3; P < .0001]), and secondary endpoints of sweat chloride (−28.3 mmol/L [95% CI: −32.1, −24.5 mmol/L; P < .0001]) and CFQ-R RD (19.5 points [95% CI: 15.5, 23.5; P < .0001]). In CFD-016, improvements in lung function were seen after treatment initiation.
Conclusions
In vitro, clinical, and real-world data support elexacaftor/tezacaftor/ivacaftor treatment in people carrying a range of CFTR variants and no F508del. The response of 84% of rare CFTR variants that produce protein to protein-stabilizing therapy suggests variants in many regions of the protein causes disease via protein destabilization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Istituto Giannina Gaslini, Genova, Italy.
- Pediatric Pulmonology and Cystic Fibrosis Unit, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain.
- Vertex Pharmaceuticals Incorporated, Boston, MA, United States.
- Division of Respiratory Medicine, Department of Medicine, St Paul's Hospital, University of British Columbia, Vancouver, Canada.
- Pneumology and Cystic Fibrosis Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
- Cystic Fibrosis Centre, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
ORCID-Profile: Federico Alghisi, Benedetta Fabrizzi, Edward F McKone, Marcus A Mall
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Castellani, C., Mondejar-Lopez, P., Van Goor, F., Quon, B. S., Alghisi, F., Fabrizzi, B., Ramsey, B., Taylor-Cousar, J. L., McKone, E. F., Tullis, E., Weinstock, T. G., Tan, V., Ahluwalia, N., Mahic, M., Liu, L., Saayman, S., Altshuler, D., Waltz, D., Mall, M. A., & Fajac, I. (2026). Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamaf001
Vancouver
Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, et al. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. American Journal of Respiratory and Critical Care Medicine. 2026. doi:10.1093/ajrccm/aamaf001
BibTeX
@article{Castellani2026,
author = {Castellani, Carlo and Mondejar-Lopez, Pedro and Van Goor, Fredrick and Quon, Bradley S and Alghisi, Federico and Fabrizzi, Benedetta and Ramsey, Bonnie and Taylor-Cousar, Jennifer L and McKone, Edward F and Tullis, Elizabeth and Weinstock, Tanya G and Tan, Vincent and Ahluwalia, Neil and Mahic, Milada and Liu, Lingyun and Saayman, Sheena and Altshuler, David and Waltz, David and Mall, Marcus A and Fajac, Isabelle},
title = {Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study},
journal = {American Journal of Respiratory and Critical Care Medicine},
year = {2026},
doi = {10.1093/ajrccm/aamaf001}
}
EUVIMED